Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.

ABSTRACT: The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi.

SUBMITTER: Lee EK

PROVIDER: S-EPMC7465003 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.

Lee Elizabeth K EK Matulonis Ursula A UA

Cancers 20200725 8

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi. ...[more]

PMID: 32722408

Similar Datasets

PARP inhibitor resistance: the underlying mechanisms and clinical implications.

Project description: Not available

| S-EPMC7305609 | biostudies-literature

Combination of PARP inhibitor and temozolomide to suppress chordoma progression.

Project description: Not available

| S-EPMC8323588 | biostudies-literature

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.

Project description: Not available

| S-EPMC8526613 | biostudies-literature

Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.

Project description: Not available

| S-EPMC6041334 | biostudies-literature

Spectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma

Project description:Multiple BRAF inhibitor resistance mechanisms have been described, however their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma. Excised progressing BRAFV600 mutant melanoma metastases (Prog) from patients treated with dabrafenib (n=22) or vemurafenib (n=8) were analyzed for known resistance mechanisms. Oncogenic signaling in Prog and matched pre-treatment tumors was examined using gene expression analysis. Resistance mechanisms were correlated with clinicopathologic features and outcome. A resistance mechanism was identified in 21/38 (55%) Prog samples from 30 patients; BRAF splice variants (n=12, 32%), N-RAS mutations (n=3, 8%), BRAF amplification (n=3, 8%), MEK1/2 mutations (n=3, 8%) and an AKT1 mutation (n=1, 3%). Four Progs tumours displayed multiple resistance mechanisms, and four patients with multiple Progs demonstrated inter-tumoral heterogeneity of resistance mechanisms. Six (21%) of 29 Progs showed loss of MAPK activity by gene expression analysis. These MAPK-inhibited Progs had unknown resistance mechanisms, and these patients had a shorter progression-free survival than patients with MAPK re-activated Progs. There were no responses to subsequent targeted therapy, even when the identified mechanism of resistance was predicted to be responsive. Heterogeneity of resistance mechanisms was common between patients, within patients and within individual tumors. The MAPK pathway remained inhibited in a subset of resistant tumors with unknown mechanisms of resistance, and the outcomes of patients with these tumors are poor. The use of sequential targeted therapies based on the molecular characteristics of a single progressing biopsy is unlikely to provide improved clinical outcomes. Total RNA was obtained from fresh-frozen melanoma tumour samples from patients before commencing treatment with dabrafenib or vemurafenib and at time of tumour progression.

2014-02-19 | E-GEOD-50509 | biostudies-arrayexpress

Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine.

Project description: Not available

| S-EPMC7139824 | biostudies-literature

Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

Project description: Not available

| S-EPMC6067963 | biostudies-literature

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

Project description: Not available

| S-EPMC6239325 | biostudies-literature

Spectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma

2014-02-19 | GSE50509 | GEO